Brief: Adverum Presents Additional Efficacy And Safety Data From Optic Trial Of ADVM-022 In Wet AMD

Adverum Biotechnologies

01/05/2022 19:20

May 1 (Reuters) - Adverum Biotechnologies Inc  ADVM.O :
    * PRESENTS ADDITIONAL EFFICACY AND SAFETY DATA FROM OPTIC
TRIAL OF
ADVM-022 IN WET AMD
    * ADVERUM - REDUCTIONS IN MEAN ANNUALIZED ANTI-VEGF
INJECTIONS
RANGED FROM 81% IN ALL PATIENTS TO 94% IN THOSE WITH NABS <1:125
AT 2 X 10^11 VG/EYE

Source text for Eikon:  ID:nGNX4xDTrZ 
Further company coverage:  ADVM.O 

 ((Reuters.Briefs@thomsonreuters.com;))